[go: up one dir, main page]

PE20080035A1 - Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina - Google Patents

Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina

Info

Publication number
PE20080035A1
PE20080035A1 PE2006001075A PE2006001075A PE20080035A1 PE 20080035 A1 PE20080035 A1 PE 20080035A1 PE 2006001075 A PE2006001075 A PE 2006001075A PE 2006001075 A PE2006001075 A PE 2006001075A PE 20080035 A1 PE20080035 A1 PE 20080035A1
Authority
PE
Peru
Prior art keywords
receptor type
activin receptor
monoclonal antibodies
human monoclonal
type kinase
Prior art date
Application number
PE2006001075A
Other languages
English (en)
Inventor
Michael Aidan North
Karin Kristina Amundson
Vahe Bedian
Shelley Sims Belouski
Dana Dan Hu-Lowe
Xin Jiang
Shannon Marie Karlicek
Sirid-Aimee Kellermann
James Arthur Thomson
Jianying Wang
Grant Raymond Wickman
Jingchuan Zhang
Original Assignee
Amgen Fremont Inc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37906640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Fremont Inc, Pfizer filed Critical Amgen Fremont Inc
Publication of PE20080035A1 publication Critical patent/PE20080035A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL O PORCION AGLUTINANTE DE ANTIGENO ANTI-ALK1 (QUINASA-1 TIPO RECEPTOR DE ACTIVINA) QUE COMPRENDE: A) UN DOMINIO VARIABLE DE LA CADENA PESADA QUE PRESENTA LAS SECUENCIAS DE AMINOACIDOS SEQ ID NO: 6, 10, 14, 18, 22, 26, ENTRE OTROS; B) UN DOMINIO VARIABLE DE LA CADENA LIGERA QUE PRESENTA LAS SECUENCIAS DE AMINOACIDOS SEQ ID NO: 8, 12, 16, 20, 24, 28, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO ANTICUERPO MONOCLONAL INHIBE LA ANGIOGENESIS SIENDO UTIL EN EL TRATAMIENTO DE CANCER, CEGUERA DIABETICA, ENDOMETRIOSIS, PSORIASIS, ARTRITIS REUMATOIDE
PE2006001075A 2005-09-07 2006-09-06 Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina PE20080035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71529205P 2005-09-07 2005-09-07

Publications (1)

Publication Number Publication Date
PE20080035A1 true PE20080035A1 (es) 2008-01-30

Family

ID=37906640

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001075A PE20080035A1 (es) 2005-09-07 2006-09-06 Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina

Country Status (40)

Country Link
US (3) US7537762B2 (es)
EP (4) EP2960253B1 (es)
JP (3) JP5161777B2 (es)
KR (3) KR101536487B1 (es)
CN (2) CN101517068B (es)
AP (2) AP2013006963A0 (es)
AR (2) AR055152A1 (es)
AU (1) AU2006297571B2 (es)
BR (1) BRPI0615766A2 (es)
CA (1) CA2621371C (es)
CL (1) CL2010000096A1 (es)
CR (3) CR9819A (es)
CY (1) CY1120794T1 (es)
DK (3) DK2960253T3 (es)
DO (1) DOP2006000195A (es)
EA (2) EA018453B1 (es)
ES (3) ES2681656T3 (es)
GE (1) GEP20125398B (es)
GT (1) GT200600406A (es)
HN (1) HN2006031275A (es)
HU (2) HUE025608T2 (es)
IL (2) IL189642A (es)
LT (1) LT2960253T (es)
MA (1) MA29843B1 (es)
ME (1) ME00501B (es)
MY (1) MY164457A (es)
NL (1) NL1032452C2 (es)
NO (1) NO20081718L (es)
NZ (1) NZ566774A (es)
PE (1) PE20080035A1 (es)
PL (3) PL1933871T3 (es)
PT (3) PT2960253T (es)
RS (1) RS54393B1 (es)
SI (3) SI2447283T1 (es)
TN (1) TNSN08080A1 (es)
TW (5) TWI541253B (es)
UA (1) UA94060C2 (es)
UY (1) UY29783A1 (es)
WO (1) WO2007040912A2 (es)
ZA (1) ZA200802971B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006091930A2 (en) * 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
DOP2006000195A (es) * 2005-09-07 2017-08-15 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
CA2623729A1 (en) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
AU2012265564B2 (en) * 2006-09-08 2016-05-26 Amgen Inc Anti-activin A antibodies and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR20150008889A (ko) 2006-11-02 2015-01-23 악셀레론 파마 인코포레이티드 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
AU2016247166B2 (en) * 2006-11-02 2018-09-27 Acceleron Pharma Inc. ALK1 receptor and ligand antagonists and uses thereof
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
AU2008236765A1 (en) * 2007-04-02 2008-10-16 Amgen Fremont Inc. Anti-IgE antibodies
ITTV20070126A1 (it) 2007-07-16 2009-01-17 Luca Toncelli Procedimento ed apparecchiatura per la fabbricazione di lastre ad effet-to venato
EP2217261B1 (en) * 2007-11-09 2015-10-07 Genentech, Inc. Activin receptor-like kinase-1 antagonist compositions and methods of use
CN101939336B (zh) * 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
RU2509085C2 (ru) * 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
US7855564B2 (en) * 2008-02-14 2010-12-21 Delaware Capital Formation, Inc. Acoustic wave device physical parameter sensor
EP2281002A2 (en) * 2008-04-25 2011-02-09 MorphoSys AG Anti-alk1 antibodies and uses thereof
TWI672151B (zh) * 2008-05-02 2019-09-21 艾西利羅製藥公司 調節血管新生與周圍細胞組成的方法與組合物
WO2009139891A2 (en) * 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010062383A2 (en) 2008-11-26 2010-06-03 Amgen Inc. Stabilized receptor polypeptides and uses thereof
WO2010126169A1 (ja) * 2009-04-30 2010-11-04 協和発酵キリン株式会社 Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
EP3441085A1 (en) 2010-06-25 2019-02-13 Vaccibody AS Homodimeric protein constructs
SG11201403367YA (en) 2011-12-19 2014-07-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP2802355B1 (en) 2012-01-09 2018-09-05 CovX Technologies Ireland Limited Mutant antibodies and conjugation thereof
WO2013155447A1 (en) 2012-04-13 2013-10-17 Children's Medical Center Corporation Tiki inhibitors
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN105431455A (zh) * 2013-02-01 2016-03-23 圣塔玛丽亚生物疗法公司 抗激活素a化合物对受试者的施用
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
EP2787006B1 (en) * 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 antibody which binding is Ca2+ dependent
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
WO2016054053A2 (en) * 2014-09-29 2016-04-07 Duke University Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
GB201503438D0 (en) 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
CA2982237A1 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
KR101983013B1 (ko) * 2015-09-25 2019-05-28 동우 화인켐 주식회사 필름 터치 센서 및 그 제조 방법
JP2017077830A (ja) * 2015-10-21 2017-04-27 Ｋｙｂ株式会社 電動パワーステアリング装置
CN108495649A (zh) 2016-01-08 2018-09-04 瓦西博迪公司 治疗性抗癌新表位疫苗
WO2017139564A1 (en) * 2016-02-11 2017-08-17 The Johns Hopkins University Compositions and methods for targeting activin signaling to treat cancer
RU2615908C1 (ru) * 2016-05-16 2017-04-11 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс
EA201990222A1 (ru) 2016-08-05 2019-07-31 МЕДИММЬЮН, ЭлЭлСи Антитела к o2 и пути их применения
CN109843917B (zh) 2016-10-19 2023-10-03 免疫医疗有限责任公司 抗o1抗体及其用途
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CN114450593A (zh) 2019-09-26 2022-05-06 美国安进公司 产生抗体组合物的方法
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN115340600B (zh) * 2020-08-19 2025-01-24 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
WO2022081824A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
EP4363456A4 (en) * 2021-06-28 2025-08-13 Trellis Bioscience Inc ANTI-ALK ANTIBODIES AND THEIR USES
CN115746142A (zh) * 2021-09-03 2023-03-07 开拓药业(广东)有限公司 抗alk-1/抗vegf双特异性抗体及其应用
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
EP4653466A1 (en) * 2023-01-18 2025-11-26 Kintor Pharmaceutical (Guangdong) Co., Ltd Anti-alk-1 antibody and use thereof
AU2024252640A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
JPH0341802A (ja) 1989-07-07 1991-02-22 Ngk Spark Plug Co Ltd 温度補償型マイクロ波ストリップラインフィルタ
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
DE69332779T2 (de) 1992-11-17 2003-10-23 Ludwig Institut For Cancer Research, Padington Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
WO1996033266A1 (en) 1995-04-21 1996-10-24 Cell Genesys, Inc. Generation of large genomic dna deletions
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5968752A (en) * 1995-08-14 1999-10-19 Creative Biomolecules, Inc. Method for identifying an OP-1 analog which binds an ALK-1 receptor
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5663272A (en) 1995-12-22 1997-09-02 Bayer Corporation Allophanate-modified diphenylmethane diisocyanates and processes for their production and use
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
DE19616523A1 (de) * 1996-04-25 1997-11-06 Basf Ag Polymerisationskatalysatoren mit beta-Diketiminat-Liganden
BR9709974A (pt) 1996-06-27 1999-08-10 Pfizer Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PE91098A1 (es) 1996-07-13 1999-01-15 Glaxo Group Ltd DERIVADOS DE PIRIDO[3,4-d]PIRIMIDINA
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ES2205242T3 (es) 1996-07-18 2004-05-01 MERCK FROSST CANADA & CO. Piridinas sustituidas COMO INHIBIDORES SELECTIVOS DE LA CICLOOXIGENASA-2`.
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
ID23978A (id) 1997-11-11 2000-06-14 Pfizer Prod Inc Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
KR20010034554A (ko) 1998-03-03 2001-04-25 레이몬드, 엠. 위티 치료제로서의 ｃｄ147 결합 분자
EP2078752A3 (en) * 1998-03-13 2009-09-23 Ludwig Institute For Cancer Research ALK-1 responds to TGF-beta and signals through SMAD-1 and SMAD-5
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
ATE289602T1 (de) 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
HK1039123A1 (zh) 1998-08-27 2002-04-12 辉瑞产品公司 用作抗癌剂的炔基取代的喹啉-2-酮衍生物
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EE05483B1 (et) 1998-12-23 2011-10-17 Pfizer, Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
HK1042096A1 (zh) 1999-02-11 2002-08-02 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉-2-酮衍生物
US5998206A (en) * 1999-02-23 1999-12-07 Isis Pharmaceuticals Inc. Antisense inhibiton of human G-alpha-12 expression
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6874343B1 (en) 1999-11-05 2005-04-05 Amada Company, Limited Press brake and method of controlling bidirectional fluid pump of hydraulic cylinder of press brake
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
DK1106612T3 (da) 1999-11-30 2004-05-17 Pfizer Prod Inc Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
NZ519546A (en) * 1999-12-15 2005-07-29 Res Dev Foundation Betaglycan as an inhibin receptor and uses thereof
HU228979B1 (en) 2000-02-15 2013-07-29 Sugen Pyrrole substituted 2-indolinone protein kinase inhibitors
US6584504B1 (en) 2000-05-26 2003-06-24 Networks Associates Technology, Inc. Method and apparatus for monitoring internet traffic on an internet web page
HUP0301120A2 (hu) 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
AU2001229563A1 (en) 2000-09-20 2002-04-02 Human Genome Sciences, Inc. 21 human secreted proteins
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
WO2003048328A2 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
JP2005516965A (ja) * 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN103087940B (zh) 2005-02-04 2015-05-13 Cp凯尔科美国公司 多糖粘液形成菌的靶基因缺失
DOP2006000195A (es) * 2005-09-07 2017-08-15 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
CN107056943B (zh) 2021-06-08
EP2960253A1 (en) 2015-12-30
AP2008004388A0 (en) 2008-04-30
EP2447283A3 (en) 2012-06-20
LT2960253T (lt) 2018-10-10
EA201300320A1 (ru) 2014-02-28
DK1933871T3 (da) 2013-07-08
PL2447283T3 (pl) 2015-12-31
HUE038941T2 (hu) 2018-12-28
KR101390127B1 (ko) 2014-05-13
CA2621371C (en) 2018-05-15
ME00501B (me) 2011-10-10
EP3381945A1 (en) 2018-10-03
PL1933871T3 (pl) 2013-09-30
TWI569807B (zh) 2017-02-11
JP2012228251A (ja) 2012-11-22
CA2621371A1 (en) 2007-04-12
TW201511773A (zh) 2015-04-01
EP2447283A2 (en) 2012-05-02
AU2006297571B2 (en) 2012-03-15
SI1933871T1 (sl) 2013-10-30
CN107056943A (zh) 2017-08-18
KR101536487B1 (ko) 2015-07-13
TWI370137B (en) 2012-08-11
EP2960253B1 (en) 2018-06-06
KR20140004261A (ko) 2014-01-10
NZ566774A (en) 2011-11-25
UY29783A1 (es) 2007-04-30
US7537762B2 (en) 2009-05-26
DK2447283T3 (en) 2015-08-31
AR107003A2 (es) 2018-03-07
AR055152A1 (es) 2007-08-08
BRPI0615766A2 (pt) 2009-06-16
JP5947840B2 (ja) 2016-07-06
US20070065444A1 (en) 2007-03-22
EP1933871B1 (en) 2013-04-24
DOP2006000195A (es) 2017-08-15
EA200800759A1 (ru) 2008-08-29
CN101517068A (zh) 2009-08-26
US20120052074A1 (en) 2012-03-01
CL2010000096A1 (es) 2010-06-25
ES2421146T3 (es) 2013-08-29
PT1933871E (pt) 2013-07-17
HK1219488A1 (en) 2017-04-07
CR20130351A (es) 2013-08-13
TW201431883A (zh) 2014-08-16
TWI453218B (zh) 2014-09-21
CR20140239A (es) 2014-06-13
EP1933871A4 (en) 2009-10-28
RS20080103A (en) 2009-07-15
TNSN08080A1 (en) 2009-07-14
HK1169999A1 (en) 2013-02-15
PL2960253T3 (pl) 2018-11-30
JP5161777B2 (ja) 2013-03-13
KR20080045715A (ko) 2008-05-23
UA94060C2 (ru) 2011-04-11
IL189642A (en) 2013-06-27
WO2007040912A3 (en) 2009-04-30
KR20130042648A (ko) 2013-04-26
EP2447283B1 (en) 2015-07-15
TWI389919B (zh) 2013-03-21
SI2447283T1 (sl) 2015-12-31
GEP20125398B (en) 2012-02-27
NL1032452A1 (nl) 2007-03-08
IL218429A0 (en) 2012-04-30
NO20081718L (no) 2008-06-03
ZA200802971B (en) 2009-10-28
ES2546069T3 (es) 2015-09-18
WO2007040912A2 (en) 2007-04-12
US8080646B2 (en) 2011-12-20
JP5833978B2 (ja) 2015-12-16
JP2009506791A (ja) 2009-02-19
GT200600406A (es) 2007-07-13
EA018453B1 (ru) 2013-08-30
RS54393B1 (sr) 2016-04-28
AU2006297571A1 (en) 2007-04-12
NL1032452C2 (nl) 2008-01-18
SI2960253T1 (sl) 2018-10-30
EP3381945B1 (en) 2020-08-19
CR9819A (es) 2008-12-03
TW200801043A (en) 2008-01-01
KR101536506B1 (ko) 2015-07-14
CY1120794T1 (el) 2019-12-11
PT2960253T (pt) 2018-07-31
HUE025608T2 (en) 2016-03-29
EP1933871A2 (en) 2008-06-25
US20100197005A1 (en) 2010-08-05
HN2006031275A (es) 2010-10-29
MA29843B1 (fr) 2008-10-03
JP2014218514A (ja) 2014-11-20
TWI541253B (zh) 2016-07-11
CN101517068B (zh) 2017-02-08
AP2013006963A0 (en) 2013-07-31
TW201311728A (zh) 2013-03-16
AU2006297571A2 (en) 2008-05-01
IL189642A0 (en) 2008-06-05
AP2723A (en) 2013-08-31
MY164457A (en) 2017-12-15
DK2960253T3 (en) 2018-08-13
TW201030017A (en) 2010-08-16
US9221915B2 (en) 2015-12-29
ES2681656T3 (es) 2018-09-14
PT2447283E (pt) 2015-10-08

Similar Documents

Publication Publication Date Title
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
PE20080846A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20120429A1 (es) Proteinas de enlace de miostatina
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
AR058983A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20131209A1 (es) Anticuerpos anti-fap
PE20121616A1 (es) Anticuerpos anti-her3
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
PE20141787A1 (es) Composiciones anti-cgrp y uso de las mismas
ES2567402T3 (es) Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
NO20082905L (no) Anti-IL-17 antistoff
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed